Fresh analysis reveals that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise regimens.
Research printed in a major medical journal demonstrates that while obese individuals can lose about a fifth of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals using these medications need to be informed of the danger of quick weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a return to starting weight in about a year and a half.
Weighing Treatments
The analysis, which looked at dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with other pills.
Scientists note that individuals who lose weight through diet and exercise generally experience a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Doctors suggest the way of the jabs explains the heightened regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, due to the likelihood of weight regain, the therapy should be considered long-term.
This opinion is echoed by pharmaceutical companies, who say that the results "underscore the chronic character of obesity," akin to managing diseases like high blood pressure.
Patient Testimonies
Individuals who have come off the medication describe a sudden return of hunger.
"It was like something activating and you become starving," said one woman.
This challenge is exacerbated if users have not established permanent dietary or behavioural changes during therapy.
Widespread Interest
Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and long-term success likely depends on combined behavioural management.
